These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15239667)

  • 1. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
    Silvestri R; Artico M; De Martino G; La Regina G; Loddo R; La Colla M; Mura M; La Colla P
    J Med Chem; 2004 Jul; 47(15):3892-6. PubMed ID: 15239667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
    Silvestri R; De Martino G; La Regina G; Artico M; Massa S; Vargiu L; Mura M; Loi AG; Marceddu T; La Colla P
    J Med Chem; 2003 Jun; 46(12):2482-93. PubMed ID: 12773052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
    Regina GL; Coluccia A; Piscitelli F; Bergamini A; Sinistro A; Cavazza A; Maga G; Samuele A; Zanoli S; Novellino E; Artico M; Silvestri R
    J Med Chem; 2007 Oct; 50(20):5034-8. PubMed ID: 17803291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
    Piscitelli F; Coluccia A; Brancale A; La Regina G; Sansone A; Giordano C; Balzarini J; Maga G; Zanoli S; Samuele A; Cirilli R; La Torre F; Lavecchia A; Novellino E; Silvestri R
    J Med Chem; 2009 Apr; 52(7):1922-34. PubMed ID: 19281225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
    Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
    J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
    Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
    J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Cesarini S; Spallarossa A; Ranise A; Schenone S; Bruno O; La Colla P; Casula L; Collu G; Sanna G; Loddo R
    Bioorg Med Chem; 2008 Jun; 16(12):6353-63. PubMed ID: 18502646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indolyl aryl sulfones (IASs): development of highly potent NNRTIs active against wt-HIV-1 and clinically relevant drug resistant mutants.
    Silvestri R; Artico M
    Curr Pharm Des; 2005; 11(29):3779-806. PubMed ID: 16305512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Rao A; Balzarini J; Carbone A; Chimirri A; De Clercq E; Monforte AM; Monforte P; Pannecouque C; Zappalà M
    Antiviral Res; 2004 Aug; 63(2):79-84. PubMed ID: 15302136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
    Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
    Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.
    O'Meara JA; Yoakim C; Bonneau PR; Bös M; Cordingley MG; Déziel R; Doyon L; Duan J; Garneau M; Guse I; Landry S; Malenfant E; Naud J; Ogilvie WW; Thavonekham B; Simoneau B
    J Med Chem; 2005 Aug; 48(17):5580-8. PubMed ID: 16107158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants.
    Cancio R; Mai A; Rotili D; Artico M; Sbardella G; Clotet-Codina I; Esté JA; Crespan E; Zanoli S; Hübscher U; Spadari S; Maga G
    ChemMedChem; 2007 Apr; 2(4):445-8. PubMed ID: 17323401
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure.
    Gatanaga H; Hachiya A; Kimura S; Oka S
    Virology; 2006 Jan; 344(2):354-62. PubMed ID: 16219331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
    Mai A; Artico M; Rotili D; Tarantino D; Clotet-Codina I; Armand-Ugón M; Ragno R; Simeoni S; Sbardella G; Nawrozkij MB; Samuele A; Maga G; Esté JA
    J Med Chem; 2007 Nov; 50(22):5412-24. PubMed ID: 17910429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
    Gao P; Song S; Frutos-Beltrán E; Li W; Sun B; Kang D; Zou J; Zhang J; Pannecouque C; De Clercq E; Menéndez-Arias L; Zhan P; Liu X
    Bioorg Med Chem; 2021 Jan; 30():115927. PubMed ID: 33352387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection.
    Klibanov OM; Kaczor RL
    Curr Opin Investig Drugs; 2010 Feb; 11(2):237-45. PubMed ID: 20112173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
    La Regina G; Coluccia A; Brancale A; Piscitelli F; Famiglini V; Cosconati S; Maga G; Samuele A; Gonzalez E; Clotet B; Schols D; Esté JA; Novellino E; Silvestri R
    J Med Chem; 2012 Jul; 55(14):6634-8. PubMed ID: 22712652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.